Haemonetics/$HAE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Haemonetics

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Ticker

$HAE
Sector

Primary listing

NYSE

Employees

3,023

Haemonetics Metrics

BasicAdvanced
$2.4B
15.12
$3.28
0.39
-

What the Analysts think about Haemonetics

Analyst ratings (Buy, Hold, Sell) for Haemonetics stock.

Bulls say / Bears say

Haemonetics reported fiscal Q4 net income of $58 million and adjusted EPS of $1.24, exceeding consensus expectations (AP via Washington Post)
In Q4, Haemonetics increased its company-adjusted gross margin by 715 basis points to 58.4%, driven by growth in Hospital segment volume and price gains across all business units (Nasdaq)
Haemonetics’ continued improvements to its NexSys PCS platform, with upgrades including Express Plus and Persona, are expected to standardize plasma collection efficiency and fuel market share gains in 2025 (Nasdaq)
The Plasma segment saw a 9.1% year-over-year decline in Q4 to $126.7 million, reflecting the impact of CSL’s contract transition and weaker organic demand (Nasdaq)
Blood Center segment revenues plunged 22.8% year-over-year in Q4 to $56.0 million due to the divestiture of the Whole Blood product line and heightened competition (Nasdaq)
RBC Capital downgraded Haemonetics to ‘Underperform’, citing higher costs that are expected to pressure earnings going forward (Bloomberg)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.

Haemonetics Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Haemonetics Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HAE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs